The charity partnership that has linked Philip Watch to the Cystic Fibrosis Research Foundation (FFC) since 2010 continues and is consolidated. The watchmaker, now part of the Morellato & Sector group, renews its commitment to solidarity for the next two years 2012/13 with a major donation of 220,000 euro to benefit two promising scientific projects aimed at identifying new strategies against lung inflammation, one of the main complications of the most widespread serious genetic disease, cystic fibrosis. The donation will also contribute to the support of the Servizio Nazionale sulle Colture Primarie, a laboratory -already under way- created by the Foundation at the Istituto G. Gaslini in Genoa, to provide high quality biological material to the scientific community engaged in CF research. The entrepreneur Matteo Marzotto, one of the founders and Vice-President of the Fondazione per la Ricerca sulla Fibrosi Cistica Onlus (Foundation for Research on Cystic Fibrosis), is once again the interpreter of the new communication campaign signed by the refined artist and great photographer Giovanni Gastel. The entire fee for the testimonial is donated by Philip Watch to FFC Onlus, a highly consistent commitment by the performers involved in this important charity project.
"A winning agreement," says Massimo Carraro, CEO of the Morellato & Sector Group to which Philip Watch belongs. "The projects adopted in the previous two years have confirmed expectations with excellent results and we are proud of this. To be able to continue to support the FFC in this endeavour is for us a commitment of great value and we hope that our contribution to these scientific projects will bring research closer to finding the long-awaited cure for cystic fibrosis".
"Together with the FFC, I would like to express my gratitude to Philip Watch for having chosen to renew its support for the Foundation, once again offering the opportunity to raise funds for studies. This is vital support for research into cystic fibrosis, which despite encouraging progress, remains a timer disease, for which there is no definitive cure," says Matteo Marzotto, adding: "Today we are experiencing a turning point. In recent years, enormous progress has been made, achieving results that have enabled us to build a bridge with the pharmaceutical industry. And it is thanks to the commitment of all those who have supported us in this endeavour that, today, the Foundation has reached such an important milestone. In fact, in a few days, an agreement will be signed with a major pharmaceutical company. A historic moment for the FFC'.
